Tranexamic Acid in Lower Extremity Endoprosthetic Reconstruction for Oncologic Indications: A Retrospective Comparative Study of 617 Patients
Journal of Surgical Oncology · 2026-06 · 133 (8) · 1089-1097
DOI: 10.1002/jso.70250 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Surgical Oncology, online erschienen am 15.04.2026. Verfasst von Stephen W Chenard und 10 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt University School of Medicine, Nashville, TN, USA. Hauptthemen laut MEDLINE: Plastic Surgery Procedures, Tranexamic Acid, Lower Extremity, Blood Loss, Surgical. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objectives While tranexamic acid (TXA) reduces blood loss in orthopedic surgery, thromboembolic concerns in cancer patients have limited adoption in orthopedic oncology. This study evaluated TXA efficacy and safety in patients undergoing endoprosthetic reconstruction for oncologic indications.
Methods
This retrospective single‐center study included 617 patients who underwent lower extremity endoprosthetic reconstruction for oncologic indications between 2000 and 2024. Patients were stratified by perioperative TXA administration ( n = 166) versus no TXA ( n = 451). The primary outcome was perioperative blood loss calculated using the Mercuriali method. Secondary outcomes included perioperative packed red blood cells (pRBC) transfusion, hospital length of stay, and 90‐day venous thromboembolic (VTE) complications.
Results
TXA was associated with a 429 mL reduction in calculated perioperative blood loss (1878 ± 1168 mL vs. 2307 ± 1442 mL; p = 0.003). TXA was not associated with reduced intraoperative pRBC transfusion rates (31% vs. 33%; RR 0.96 [95% CI: 0.74–1.25], p = 0.752) but was associated with significantly reduced postoperative transfusion requirements (17% vs. 30%; RR 0.56 [95% CI: 0.39–0.81], p = 0.003). No significant differences existed in 90‐day VTE complications, reoperation rates, or mortality.
Conclusions
Perioperative TXA use was associated with reduced blood loss and postoperative transfusion requirements without a detectable increase in thromboembolic complications, supporting TXA as a beneficial adjunct in musculoskeletal oncology limb salvage procedures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vanderbilt University School of Medicine, Nashville, TN, USA.
- Center for Bone Biology, Vanderbilt University Medical Center, Nashville, TN, USA.
- Program in Cancer Biology, Vanderbilt University, Nashville, TN, USA.
- Department of Orthopaedic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
- Department of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, TN, USA.
- Department of Pharmacology, Vanderbilt University, Nashville, TN, USA.
ORCID-Profile: Stephen W Chenard
Zitieren
APA
Chenard, S. W., Rekulapelli, A., Gilbertson, R. S., Charton, C. S., Hefley, W. F., Colello, M. J., Halpern, J. L., Schwartz, H. S., Johnson, D. J., Schoenecker, J. G., & Lawrenz, J. M. (2026). Tranexamic Acid in Lower Extremity Endoprosthetic Reconstruction for Oncologic Indications: A Retrospective Comparative Study of 617 Patients. Journal of Surgical Oncology, 133(8), 1089-1097. https://doi.org/10.1002/jso.70250
Vancouver
Chenard SW, Rekulapelli A, Gilbertson RS, Charton CS, Hefley WF, Colello MJ, et al. Tranexamic Acid in Lower Extremity Endoprosthetic Reconstruction for Oncologic Indications: A Retrospective Comparative Study of 617 Patients. Journal of Surgical Oncology. 2026;133(8):1089-1097. doi:10.1002/jso.70250
BibTeX
@article{Chenard2026,
author = {Chenard, Stephen W and Rekulapelli, Akhil and Gilbertson, Riley S and Charton, Connor S and Hefley, William F and Colello, Michael J and Halpern, Jennifer L and Schwartz, Herbert S and Johnson, Daniel J and Schoenecker, Jonathan G and Lawrenz, Joshua M},
title = {Tranexamic Acid in Lower Extremity Endoprosthetic Reconstruction for Oncologic Indications: A Retrospective Comparative Study of 617 Patients},
journal = {Journal of Surgical Oncology},
year = {2026},
volume = {133},
number = {8},
pages = {1089--1097},
doi = {10.1002/jso.70250}
}
EUVIMED